LBRX NASDAQ
LB Pharmaceuticals Inc Common Stock
1W: +1.4%
1M: +5.4%
3M: +12.6%
YTD: +92.5%
1Y: +148.4%
$39.64
+0.30 (+0.76%)
After Hours: $43.55 (+3.91, +9.85%)
Weekly Expected Move ±8.8%
$32
$35
$39
$42
$46
Credit Risk of going bust: lower than 80% of companies Debt: 0.4% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.02 (down 99.9%), LB Pharmaceuticals Inc Common Stock would be worth roughly what it owes.
Total debt $5.2M against a stock market value of $1.27B.
Distance to default 9.69 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $2.6M (short-term plus half of long-term), stock volatility 62.4%; Altman Z'' 14.47. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.02 (down 99.9%), LB Pharmaceuticals Inc Common Stock would be worth roughly what it owes.
Total debt $5.2M against a stock market value of $1.27B.
Distance to default 9.69 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $2.6M (short-term plus half of long-term), stock volatility 62.4%; Altman Z'' 14.47. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.3B
52W Range14.317-50.16
Volume275,975
Avg Volume373,725
Beta0.42
Dividend—
Analyst Ratings
Company Info
CEOHeather D. Turner
Employees49
SectorHealthcare
IndustryBiotechnology
IPO Date2025-09-11
Websitelbpharma.us
One Pennsylvania Plaza
New York, NY 10119
US
New York, NY 10119
US
212 605 0300
About LB Pharmaceuticals Inc Common Stock
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.
Latest News
Bank of New York Mellon Corp Makes New $1.78 Million Investment in LB Pharmaceuticals Inc $LBRX
LB Pharmaceuticals appoints Joseph Miller as CFO
LB Pharmaceuticals Appoints Joseph Miller as Chief Financial Officer
LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
All You Need to Know About LB Pharmaceuticals Inc (LBRX) Rating Upgrade to Buy
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Miller Joseph M | A-Award | 200,000 | $37.22 | 2026-10-09 |
| Kozauer Susan Gani | A-Award | 200,000 | $37.22 | 2026-10-09 |
| Kozauer Susan Gani | 0 | — | 2026-09-14 |